Business
YTD and Q3 2022 Results
YTD and Q3 2022 Results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n AstraZeneca PLC\n \n \n 10 November 2022 07:00 GMT \n \n \n YTD and Q3 2022 results\n \n \n \n \n \n Record number of regulatory approvals and guidance uplift underpinned by strong business performance\n \n \n \n \n \n \n Revenue and EPS summary\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n YTD 2022 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Q3 2022 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n % Change\n \n \n \n \n \n \n \n \n \n \n \n % Change \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n $m \n \n \n \n \n \n \n Actual \n \n \n \n \n \n \n CER[1]\n \n \n \n \n \n \n $m \n \n \n \n \n \n \n Actual \n \n \n \n \n \n \n CER \n \n \n \n \n \n \n \n - Product Sales \n \n \n \n \n \n \n \n \n \n \n \n 32,200 \n \n \n \n \n 29 \n \n \n \n \n 35 \n \n \n \n \n 10,590 \n \n \n \n \n 9 \n \n \n \n \n 16 \n \n \n \n \n \n \n - Collaboration Revenue \n \n \n \n \n \n \n \n \n \n \n \n 944 \n \n \n \n \n >2x \n \n \n \n \n >2x \n \n \n \n \n 392 \n \n \n \n \n >3x \n \n \n \n \n >3x \n \n \n \n \n \n \n Total Revenue \n \n \n \n \n \n \n \n \n \n \n \n 33,144 \n \n \n \n \n 30 \n \n \n \n \n 37 \n \n \n \n \n 10,982 \n \n \n \n \n 11 \n \n \n \n \n 19 \n \n \n \n \n \n \n Reported[2] EPS\n \n [3]\n \n \n \n \n \n \n \n \n \n \n \n \n $1.54 \n \n \n \n \n >4x \n \n \n \n \n >4x \n \n \n \n \n $1.06 \n \n \n \n \n n/m \n \n \n \n \n n/m \n \n \n \n \n \n \n Core[4] EPS \n \n \n \n \n \n \n \n \n \n \n \n $5.28 \n \n \n \n \n 47 \n \n \n \n \n 52 \n \n \n \n \n $1.67 \n \n \n \n \n 55 \n \n \n \n \n 70 \n \n \n \n \n \n \n \n \n \n YTD 2022 Financial performance\n (\n growth\n numbers\n and\n commentary at CER\n \n [5]\n \n )\n \n \n \n \n \n ‒\n Total Revenue increased 37% to $33,144m, with growth coming from all disease areas, and from the addition of Alexion, which was incorporated into the Group's results from 21 July 2021\n \n \n \n \n \n ‒\n Oncology Total Revenue increased 24%, inclusive of...